Accendra Health Inc/va/ (ACH) · Nov 2, 2026 · Material agreement
$150M facility extended — Termination extended to October 2029; facility size remains $150M
Accendra Health’s financing amendment extends its $150M receivables sale program to October 2029, supporting liquidity without expanding capacity.
Accendra Health is now a focused Apria-and-Byram home-based-care company, operating through a post-divestiture balance-sheet reset and relying on receivables funding alongside its revolver and cash to support working capital. Its prior filing showed the $150 million receivables program was scheduled to terminate on October 18, 2027, while the company was also extending and reshaping other debt maturities.
The amendment removes a meaningful near-term refinancing deadline. The receivables sale program now runs to October 2029, two years beyond the prior scheduled end date, while the facility remains $150 million.
| Facility | Current terms | Prior terms |
|---|---|---|
| Receivables sale program (Exhibit 99.1) | $150M through October 2029 | $150M through October 2027 |
This is a liquidity extension, not new funding capacity. The unchanged $150 million ceiling means the filing improves duration and reduces rollover pressure, but it does not increase the cash Accendra can raise against receivables. The amendment also revises account-control and reporting requirements, though the filing does not disclose terms that would materially change economics. 〔0〕
The signal is modestly constructive because financing access is being preserved during a balance-sheet transition. The company had identified this program as a primary liquidity source, and the extension supports the focused Apria/Byram business while other debt restructuring work continues. But because the facility size is unchanged and no borrowing, pricing, or covenant benefit is disclosed, this is maintenance of the liquidity framework rather than a step-change in financial strength.
Bottom line: Accendra buys two more years of receivables-financing runway, which modestly strengthens its post-divestiture liquidity setup. It matters, but the unchanged capacity keeps this from being a major balance-sheet improvement.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!